ANAVEX New Website - Untitled Page.png

News, Events and Updates

Search

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FragileX Syndrome

Aug 26

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FragileX Syndrome

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result

Aug 12

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result

Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits

Jul 29

Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits

Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data

Dec 21, 2020

Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data

Anavex Life Sciences Announces Completion of ANAVEX®2-73 U.S. Phase 2 Rett Syndrome Clinical Trial

Sep 10, 2020

Anavex Life Sciences Announces Completion of ANAVEX®2-73 U.S. Phase 2 Rett Syndrome Clinical Trial

Stay Connected

Follow us on social media

Webcast Library

Back to Newsroom

Quick Links

Therapeutic Candidates

Patients & Carers

Resources

Corporate Presentation

Forward-Looking Statements

Join our mailing list

Name

Email

Thank you for subscribing!

ANAVEX® is a trademark of Anavex Life Sciences Corp. © 2007-2021. All Rights Reserved.